May 3, 2018 / 5:43 PM / 18 days ago

BRIEF-Nanobiotix Partners With Weill Cornell Medicine

May 3 (Reuters) - NANOBIOTIX SA:

* PARTNERS WITH WEILL CORNELL MEDICINE

* PARTNERSHIP ON PRE-CLINICAL STUDIES TO EVALUATE NBTXR3 IMPACT ON CGAS-STING PATHWAY IN MAMMARY CANCERS

* TRIAL THAT SHALL START IN Q2 2018, AIMS TO EXPAND POTENTIAL OF NBTXR3

* COLLABORATION WILL BE CONDUCTED OVER COURSE OF 1 YEAR, WITH GOAL OF CONTINUING EXPLORATION OF ROLE OF NBTXR3 IN IMMUNO-ONCOLOGY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below